01/31/2018
RICHLAND, Jan. 31, 2018 (GLOBE NEWSWIRE) -- - IsoRay, Inc. (the “Company”) (NYSE American: ISR), a medical ...
01/24/2018
Revenue Increase Driven by Increasing Traction of New Sales Strategies in Prostate Brachytherapy
RICHLAND, Wash, ...
01/09/2018
Possible Evidence of Paradigm Shift in the Radiation Treatment of Cancers Afflicting the Brain
RICHLAND, Wash.,, ...
01/08/2018
10 Year Exclusive Agreement to Supply Proprietary Cesium-131 Seeds Embedded in Collagen Tiles
RICHLAND, Wash., ...
11/14/2017
Revenue of $1.21 Million, 12% First Quarter-Over-First Quarter Increase, Gross Margin of 22% RICHLAND, Wash., ...
11/09/2017
Potential New Application for Cesium-131 for Unmet Medical Need
RICHLAND, Wash., Nov. 09, 2017 (GLOBE NEWSWIRE) --
09/28/2017
Gross Margin Expands to 36% on Continued Process Improvements and Expense Reduction
RICHLAND, Wash., Sept. 28, ...
09/26/2017
Study Demonstrates Ability to Control Local Disease Over Reasonably Long Period of Time, A Major Step in Preserving
09/25/2017
9 Year Study Demonstrates Durable Positive Outcomes and Statistically Identical Results of Cesium-131
RICHLAND, ...
08/31/2017
RICHLAND, Wash., Aug. 31, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and ...
08/04/2017
Gross Margin Expands Significantly to 31% on Ongoing Process Improvements and Expense Reduction
RICHLAND, ...
07/07/2017
RICHLAND, Wash., July 7, 2017 -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed ...
Media & Public Relations Contact
If you have questions or need help, please contact Sharon Schultz:
Sharon Schultz
Public and Media Relations